Journal
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
Volume 11, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1759720X19864492
Keywords
cartilage; corticosteroids; DMOAD; inflammation; nociceptive pain; osteoarthritis; synovitis
Categories
Funding
- Versus Arthritis Experimental Osteoarthritis Treatment Centre [20083]
- NIHR through the Leeds Biomedical Research Centre
Ask authors/readers for more resources
Osteoarthritis (OA) is a chronic painful arthritis with increasing global prevalence. Current management involves non-pharmacological interventions and commonly used pharmacological treatments that generally have limited analgesic efficacy and multiple side effects. New treatments are therefore required to relieve patient symptoms and disease impact. A number of existing pharmacological therapies have been recently trialled in OA. These include extended-release triamcinolone and conventional disease-modifying anti-rheumatic drugs (DMARDs) used in the management of rheumatoid arthritis; generally, DMARDs have not shown a benefit in treating OA. Novel analgesic therapies are in development, including those targeting peripheral pain pathways. Disease-modifying osteoarthritis drugs (DMOADs) target key tissues in the OA pathophysiology process and aim to prevent structural progression; a number of putative DMOADs are in phase II development. There is preliminary evidence of structural improvement with some of these therapies but without concomitant symptom improvement, raising new considerations for future DMOAD trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available